U S PHYSICAL THERAPY INC /NV Revenue
U S PHYSICAL THERAPY INC /NV (USPH) reported Revenue of $214.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-07
- U S PHYSICAL THERAPY INC /NV revenues for the quarter ending 2026-06-30 was $214.06M, a 8.47% increase year-over-year.
- U S PHYSICAL THERAPY INC /NV revenues for the quarter ending 2026-03-31 was $198.29M, a 7.89% increase year-over-year.
- U S PHYSICAL THERAPY INC /NV revenues for the quarter ending 2025-12-31 was $202.73M, a 12.35% increase year-over-year.
- U S PHYSICAL THERAPY INC /NV revenues for the quarter ending 2025-09-30 was $197.13M, a 17.32% increase year-over-year.
- U S PHYSICAL THERAPY INC /NV revenues for fiscal 2025 was $780.99M, a 16.33% increase from fiscal 2024.
- U S PHYSICAL THERAPY INC /NV revenues for fiscal 2024 was $671.35M, a 11.00% increase from fiscal 2023.
- U S PHYSICAL THERAPY INC /NV revenues for fiscal 2023 was $604.80M, a 9.34% increase from fiscal 2022.
- U S PHYSICAL THERAPY INC /NV revenues for fiscal 2022 was $553.14M, a 11.74% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $214.06M 10-Q · filed 2026-08-07 | $412.34M 10-Q · filed 2026-08-07 | $615.07M derived: sum of 3 quarters · filed 2026-08-07 | $812.20M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $198.29M 10-Q · filed 2026-05-08 | $401.01M derived: sum of 2 quarters · filed 2026-05-08 | $598.14M derived: sum of 3 quarters · filed 2026-05-08 | $795.49M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $202.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $399.86M derived: sum of 2 quarters · filed 2026-02-27 | $597.20M derived: sum of 3 quarters · filed 2026-08-07 | $780.99M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $197.13M 10-Q · filed 2025-11-07 | $394.48M derived: sum of 2 quarters · filed 2026-08-07 | $578.26M 10-Q · filed 2025-11-07 | $758.71M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $197.34M 10-Q · filed 2026-08-07 | $381.13M 10-Q · filed 2026-08-07 | $561.58M derived: sum of 3 quarters · filed 2026-08-07 | $729.61M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $183.79M 10-Q · filed 2026-05-08 | $364.24M derived: sum of 2 quarters · filed 2026-05-08 | $532.27M derived: sum of 3 quarters · filed 2026-05-08 | $699.46M derived: sum of 4 quarters · filed 2026-05-08 | ||
| 2024-12-31 | $180.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $348.48M derived: sum of 2 quarters · filed 2026-02-27 | $515.67M derived: sum of 3 quarters · filed 2026-02-27 | $671.35M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $168.03M 10-Q · filed 2025-11-07 | $335.22M derived: sum of 2 quarters · filed 2025-11-07 | $490.90M 10-Q · filed 2025-11-07 | $645.70M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-06-30 | $167.19M 10-Q · filed 2025-08-08 | $322.87M 10-Q · filed 2025-08-08 | $477.67M derived: sum of 3 quarters · filed 2026-02-27 | $627.67M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-03-31 | $155.68M 10-Q · filed 2025-05-09 | $310.48M derived: sum of 2 quarters · filed 2026-02-27 | $460.48M derived: sum of 3 quarters · filed 2026-02-27 | $611.97M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $154.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $304.81M derived: sum of 2 quarters · filed 2026-02-27 | $456.29M derived: sum of 3 quarters · filed 2026-02-27 | $604.80M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $150.01M 10-Q · filed 2024-11-08 | $301.49M derived: sum of 2 quarters · filed 2024-11-08 | $450.00M 10-Q · filed 2024-11-08 | $591.18M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $151.49M 10-Q · filed 2024-08-14 | $299.99M 10-Q · filed 2024-08-14 | $441.18M derived: sum of 3 quarters · filed 2025-03-03 | $580.78M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | $148.51M 10-Q · filed 2024-05-08 | $289.69M derived: sum of 2 quarters · filed 2025-03-03 | $429.29M derived: sum of 3 quarters · filed 2025-03-03 | $569.95M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $141.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $280.78M derived: sum of 2 quarters · filed 2025-03-03 | $421.44M derived: sum of 3 quarters · filed 2025-03-03 | $553.14M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $139.60M 10-Q · filed 2023-11-08 | $280.26M derived: sum of 2 quarters · filed 2023-11-08 | $411.96M 10-Q · filed 2023-11-08 | $541.79M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $140.66M 10-Q · filed 2023-08-09 | $272.36M 10-Q · filed 2023-08-09 | $402.19M derived: sum of 3 quarters · filed 2024-02-29 | $528.09M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-03-31 | $131.70M 10-Q · filed 2023-05-05 | $261.54M derived: sum of 2 quarters · filed 2024-02-29 | $387.43M derived: sum of 3 quarters · filed 2024-02-29 | $514.36M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $129.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $255.73M derived: sum of 2 quarters · filed 2024-02-29 | $382.65M derived: sum of 3 quarters · filed 2024-02-29 | $495.02M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $125.89M 10-Q · filed 2022-11-08 | $123.58M 10-Q · filed 2021-11-09 | $252.82M derived: sum of 2 quarters · filed 2022-11-08 | $365.19M 10-Q · filed 2022-11-08 | $357.58M 10-Q · filed 2021-11-09 | $488.40M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $126.93M 10-Q · filed 2022-08-08 | $239.30M 10-Q · filed 2022-08-08 | $362.51M derived: sum of 3 quarters · filed 2023-02-28 | $469.43M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | $112.37M 10-Q · filed 2022-05-09 | $235.58M derived: sum of 2 quarters · filed 2023-02-28 | $342.50M derived: sum of 3 quarters · filed 2023-02-28 | $426.36M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $123.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $230.13M derived: sum of 2 quarters · filed 2023-02-28 | $313.99M derived: sum of 3 quarters · filed 2023-02-28 | $422.97M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $106.92M 10-Q · filed 2021-11-09 | $108.93M 10-Q · filed 2020-11-06 | $190.78M derived: sum of 2 quarters · filed 2021-11-09 | $299.76M 10-Q · filed 2021-11-09 | $305.50M 10-Q · filed 2020-11-06 | $425.61M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $83.86M 10-Q · filed 2021-08-09 | $196.57M 10-Q · filed 2021-08-09 | $318.69M derived: sum of 3 quarters · filed 2022-03-01 | $435.94M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $112.72M 10-Q · filed 2021-05-10 | $234.83M derived: sum of 2 quarters · filed 2022-03-01 | $352.08M derived: sum of 3 quarters · filed 2022-03-01 | $478.45M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $122.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $239.37M derived: sum of 2 quarters · filed 2022-03-01 | $365.74M derived: sum of 3 quarters · filed 2022-03-01 | $481.97M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $117.25M 10-Q · filed 2020-11-06 | $243.62M derived: sum of 2 quarters · filed 2020-11-06 | $359.86M 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $126.37M 10-Q · filed 2020-08-07 | $242.60M 10-Q · filed 2020-08-07 | ||||
| 2018-12-31 | $453.91M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |